Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Short term Debt (2016 - 2025)

Ironwood Pharmaceuticals' Short term Debt history spans 8 years, with the latest figure at $199.7 million for Q4 2025.

  • For Q4 2025, Short term Debt changed N/A year-over-year to $199.7 million; the TTM value through Dec 2025 reached $199.7 million, changed N/A, while the annual FY2025 figure was $199.7 million, N/A changed from the prior year.
  • Short term Debt for Q4 2025 was $199.7 million at Ironwood Pharmaceuticals, roughly flat from $199.5 million in the prior quarter.
  • Across five years, Short term Debt topped out at $199.8 million in Q1 2024 and bottomed at $112.9 million in Q2 2021.
  • The 5-year median for Short term Debt is $199.3 million (2023), against an average of $169.2 million.